$8.180
+0.070 (+0.86%)收盘时
HBIO 资讯
HBIO 事件
Reaffirms FY26 Adjusted Gross Margin Outlook Between 58%-60%
Reaffirms FY26 adjusted gross margin outlook between 58%060% and adjusted EBITDA growth between 6%-10%.
Sees Q2 Adjusted Gross Margin Between 57%-59%
Sees Q2 adjusted gross margin between 57%-59%. Sees Q2 adjusted EBITDA between $1M-$2M. Expects year-over-year revenue growth in the mid-single digit range at the midpoint of guidance.
Company Reports Q1 Revenue of $20.8M
Reports Q1 revenue $20.8M vs. $21.8M last year. The company noted encouraging adoption rates within its NPI portfolio, specifically the MeshMEA organoid platform and BTX Electroporation systems, which is driving a shift toward a higher-margin product mix. "First quarter revenues were in line with our expectations and gross margin expanded year-over-year, while we remained profitable on an adjusted EBITDA basis," said CEO John Duke.
Mark Frost Appointed CFO on Permanent Basis
Interim CFO Mark Frost Appointed CFO on Permanent Basis
Harvard Bioscience Reports Q4 Revenue of $23.735M
Reports Q4 revenue $23.735M vs $24.556M last year. "2025 was a pivotal year for Harvard Bioscience as we strengthened our balance sheet and streamlined our operating model. This culminated in fourth quarter results that reflect disciplined execution, an improved product mix, and the cost reductions implemented throughout the year," said John Duke, President and Chief Executive Officer. "As we look ahead, we are evolving from a traditional life science tools provider into a leading enabler of translational science. By embracing the ongoing shift to New Approach Methodologies and focusing on new products for translational science, we'll help our customers generate more predictive, human-relevant data earlier in the drug development process. We believe we are well-positioned for a new phase of growth and are confident in our outlook and our ability to drive sustainable shareholder value in 2026 and beyond."
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。